Search Results 221-230 of 16716 for alt

1. Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors - Mayo Clinic

   AST/ALT ≤ 3 x ULN and total bilirubin ≤ 2.0 x ULN. In metastatic disease to the liver, AST/ALT may be ≤ 5x ULN and total bilirubin ≤ 2.5 x ULN. If known ...

2. Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer - Mayo Clinic

   ... [ALT]) ≤ 3 x ULN or SGOT (AST) and SGPT (ALT) ≤ 5 x ULN if elevations are due to liver metastases. - Alkaline phosphatase ≤ 2.5 x ULN or alkaline ...

3. Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) - Mayo Clinic

   - ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase);. AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); ...

4. A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression - Mayo Clinic

   Significant unstable medical condition; Hepatic insufficiency (2.5 X ULN for AST or ALT), past liver transplant recipient, and/or clinical diagnosis of ...

5. A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) - Mayo Clinic

   ALT: males > 250 IU/L and females > 200 IU/L;; Total Bilirubin > 2.5 mg/dL. International normalized ratio (INR) ≥ 1.2. Subjects on anticoagulant therapy ...

6. Pazopanib Hydrochloride in Treating Patients with Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma - Mayo Clinic

   ... (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 x ULN; NOTE: Subjects who have both bilirubin > ULN and AST/ALT > ULN are not eligible; Alkaline ...

7. Liver transplant - Doctors & Departments - Mayo Clinic

   Joo DJ, et al. Bioartificial liver support for acute liver failure. Annals of Liver Transplantation. 2025; doi:10.52604/alt.25.0004. Taner T, et al. Summary of ...

8. PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial

   ALT/AST >= 3 x ULN; Bilirubin >= 3 mg/dL at Screening; Any known factor or disease that might interfere with treatment compliance, study conduct, or ...

9. A Study to Evaluate the Safety and Effectiveness of BMS-986036 (pegbelfermin) in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Fibrosis - Mayo Clinic

   Evidence of significant worsening of ALT, AST or bilirubin during the Screening Period, in the opinion of the investigator or medical monitor. A centrally read ...

10. Omega-3 Fatty Acids and Insulin Sensitivity - Mayo Clinic

    Chronic active liver disease (AST>144IU/L and ALT>165IU/L); Anti-coagulant therapy (warfarin/heparin); INR >3; Use of systemic glucocorticoids; Chronic use of ...